Winner Medical(SZ:300888) Southwest Securities·2025-06-10 05:23Investment Rating - The report maintains a "Buy" rating for the company, citing strong growth potential in both its medical and consumer segments [4]. Core Views - The company is positioned for a growth year, driven by a dual engine of medical and consumer sectors, with a focus on brand development and market expansion [4]. - The medical segment is expected to benefit from both organic growth and acquisitions, while the consumer segment is leveraging its brand strength to capture market share [4][27]. - The company has implemented a stock incentive plan to align employee interests with long-term growth targets, reflecting confidence in future performance [18]. Summary by Sections Company Overview - The company, established in 1991, operates through two main brands: "Winner" for medical products and "Purcotton" for consumer goods, achieving synergy between the two sectors [7][45]. - It has a comprehensive product matrix in the medical field, including traditional wound care, high-end dressings, and health personal care products, while the consumer segment focuses on cotton-based products [7][46]. Medical Segment - The medical segment is focused on consumables, with a robust product offering and a growing market driven by aging populations and increased healthcare needs [50][61]. - Revenue from the medical segment reached 39.1 billion in 2024, with a year-on-year growth of 1.1%, while Q1 2025 saw a significant increase of 46.3% [27][24]. - The acquisition of the American company GRI is expected to enhance global production and logistics capabilities, contributing 2.9 billion to revenue in 2024 [4][27]. Consumer Segment - The consumer segment has shown strong growth, with revenue increasing from 13.3 billion in 2016 to 49.9 billion in 2024, reflecting a compound annual growth rate (CAGR) of 25.6% [4][27]. - Key products such as cotton wipes and sanitary napkins have seen substantial growth, with Q1 2025 revenues for these products increasing by 73.5% and 38.6% respectively [4][27]. Financial Forecast and Valuation - The company is projected to achieve net profits of 10.1 billion, 12.7 billion, and 15.6 billion from 2025 to 2027, representing year-on-year growth rates of 45.2%, 25.9%, and 22.9% respectively [4]. - The report suggests that the company's strong brand presence and market strategies will continue to drive growth, justifying the "Buy" rating [4].